↓ Skip to main content

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

Overview of attention for article published in Frontiers in immunology, December 2021
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
7 X users

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
43 Mendeley